SIG002 / Arugula Sci - LARVOL DELTA

Shielded Living Therapeutics platform for the treatment of type 1 diabetes (IPITA-IXA-CTRMS 2023) - "We have shown that SIG-002 is efficacious and that Afibromer alginate mitigates the foreign body response. With these encouraging preclinical data, we have laid the foundation for achieving our goal of developing a functional cure for T1D."

Diabetes • Fibrosis • Metabolic Disorders • Type 1 Diabetes Mellitus

Arugula Sciences announces FDA Approval to Proceed with Phase 1 Study of SIG002, a Perinatal-derived Secretome Product, for the Treatment of Big Toe Osteoarthritis (Hallux Rigidus) (Businesswire) - "Arugula Sciences announced today that it has received clearance from the FDA for its investigational new drug (IND) application for a Phase 1, open-label, dose-ranging clinical trial of SIG002, a perinatal-derived secretome product. This trial will assess the safety, tolerability, preliminary efficacy, and dose effect of SIG002 in patients with symptomatic osteoarthritis of the first metatarsophalangeal joint....For this clinical trial, Arugula Sciences has partnered with Dr. Matthew Negaard at the Forte Orthopedic Research Institute, a not-for-profit organization associated with the Forte Sports Medicine and Orthopedics clinic in Carmel, IN. Enrolled participants with moderate HR will receive an ultrasound-guided intra-articular injection of SIG002 and will be monitored in subsequent months for safety and preliminary efficacy signals. The first participant is expected to be enrolled in February 2023."

IND • New P1 trial • CNS Disorders • Osteoarthritis • Pain